Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 6:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 66 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Metabolic Dysfunction-associated Steatohepatitis Clear all
Recruiting Phase 2 Interventional

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

NCT07288138
View directory record Official record
Conditions
Metabolic Dysfunction-associated Steatohepatitis
Interventions
Placebo, ECC4703, ECC0509
Drug
Lead sponsor
Eccogene
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
64
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 17, 2026, 6:24 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)

NCT06836609
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
Interventions
ALN-CIDEB, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Chandler, Arizona • Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 17, 2026, 6:24 PM EDT
Recruiting Phase 2 Interventional

Study of Resmetirom in Children and Adolescents With MASH

NCT07763015
View directory record Official record
Conditions
MASH, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
Resmetirom
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 17, 2026, 6:24 PM EDT
Not yet recruiting Phase 1 Interventional

Human Models of Selective Insulin Resistance: Pancreatic Clamp

NCT06558422
View directory record Official record
Conditions
Insulin Resistance, Hyperinsulinemia, Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Growth Hormone, Human, 20% D-glucose (aq), [6,6-2H2] D-glucose, [1-13C1] sodium acetate, Nestle BOOST Plus, KIND Bar, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer
Drug · Diagnostic Test · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 17, 2026, 6:24 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease

NCT05332613
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
TRE plus SOC, SOC, TRE
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 17, 2026, 6:24 PM EDT
Recruiting Phase 3 Interventional

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

NCT07165028
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions
Tirzepatide, Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
4,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
142
States / cities
Tuscaloosa, Alabama • Chandler, Arizona • Gilbert, Arizona + 123 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Behavioral Lifestyle Intervention for Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Adults

NCT06121999
View directory record Official record
Conditions
Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD), Metabolic Associated-dysfunction Steatohepatitis (MASH)
Interventions
Standard of care acceptance-based behavioral weight loss program, Occupational therapy dietary and lifestyle modifications
Behavioral
Lead sponsor
Grand Valley State University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Wyoming, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Sep 17, 2026, 6:24 PM EDT
Recruiting Phase 3 Interventional

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

NCT06632457
View directory record Official record
Conditions
Metabolic Dysfunction Associated Steatohepatitis
Interventions
Survodutide, Placebo matching survodutide
Combination Product
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
126
States / cities
Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 17, 2026, 6:24 PM EDT
Enrolling by invitation Not applicable Interventional

Improving Diagnostic Safety Through STeatosis Identification, Risk Stratification, and Referral in the ED

NCT06944353
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Steatosis of Liver, Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions
STIRRED
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
4,704 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 17, 2026, 6:24 PM EDT
Recruiting Phase 2 Interventional

Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

NCT07335601
View directory record Official record
Conditions
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
Resmetirom, Placebo
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 17, 2026, 6:24 PM EDT
Not yet recruiting Phase 4 Interventional

Nutrition Intervention Combined With Resmetirom for MASH

NCT07680478
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Interventions
Resmetirom therapy, Comprehensive nutritional intervention, Standard dietary support
Drug · Behavioral
Lead sponsor
City University of New York
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 17, 2026, 6:24 PM EDT
Recruiting Not applicable Interventional

Time-restricted Eating and Healthy Eating in Patients With Metabolic Liver Disease or Cancer

NCT06824974
View directory record Official record
Conditions
Liver Cancer, Adult, MASH - Metabolic Dysfunction-Associated Steatohepatitis, Obesity and Overweight
Interventions
Time-restricted eating plus healthy diet
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 17, 2026, 6:24 PM EDT
Active, not recruiting Not applicable Interventional

Influence of Metabolic Syndrome on Endogenous Oxalate Synthesis

NCT06735924
View directory record Official record
Conditions
MASLD, Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions
Low-oxalate fixed diet
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 17, 2026, 6:24 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Thermoacoustic Method for Estimating Liver Fat Fraction

NCT07321925
View directory record Official record
Conditions
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Fatty Liver Disease, Nonalcoholic
Interventions
Thermoacoustic Enhanced Ultrasound
Device
Lead sponsor
Endra Lifesciences
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 17, 2026, 6:24 PM EDT
Recruiting Not applicable Interventional

Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial

NCT06138821
View directory record Official record
Conditions
Obesity, Liver Diseases, Liver Fibrosis, Liver Fat, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, MASLD, MASH, Weight Loss, Insulin Resistance, Insulin Sensitivity, Insulin Sensitivity/Resistance, Metabolic Disease, Diabetes, Diabetes Mellitus, Type 2, NASH With Fibrosis, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non-alcoholic Steatohepatitis
Interventions
ESG + lifestyle modification, Lifestyle modification
Device · Behavioral
Lead sponsor
Pichamol Jirapinyo, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Not applicable Interventional

Feasibility of Immersive Virtual Reality Dietician Program in Metabolic-dysfunction Associated Steatotic Liver Disease

NCT06215131
View directory record Official record
Conditions
Fatty Liver, Nonalcoholic, Weight Loss, Virtual Reality, Implementation Science
Interventions
In-person dietary weight loss counseling, Virtual reality dietary weight loss counseling
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 17, 2026, 6:24 PM EDT
Recruiting Phase 2 Interventional

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

NCT06920043
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease
Interventions
Efimosfermin, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
28
States / cities
Chandler, Arizona • Mesa, Arizona • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 17, 2026, 6:24 PM EDT
Recruiting Phase 2 Interventional

SMART Diets for MASLD

NCT07459504
View directory record Official record
Conditions
Metabolic-dysfunction Associated Steatotic Liver Disease
Interventions
Essential Amino Acids Supplementation intervention, Low sugar diet
Drug · Other
Lead sponsor
Michigan State University
Other
Eligibility
11 Years to 17 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 17, 2026, 6:24 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH Participants

NCT07512427
View directory record Official record
Conditions
MASH
Interventions
OPK-88006, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 17, 2026, 6:24 PM EDT
Recruiting Phase 2 Interventional

A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)

NCT07325526
View directory record Official record
Conditions
Liver Cirrhosis
Interventions
BI 3802876, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
26
States / cities
Chandler, Arizona • Coronado, California • La Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 17, 2026, 6:24 PM EDT
Recruiting Phase 3 Interventional

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

NCT07221227
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
Efimosfermin alfa, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
74
States / cities
Chandler, Arizona • Tucson, Arizona • Little Rock, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 17, 2026, 6:24 PM EDT
Recruiting Not applicable Interventional

Quantitative Ultrasound(DeepUSFF) vs MRI-PDFF for Liver Fat Assessment in MASLD

NCT07192159
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease, Hepatic Steatosis, Liver Disease Parenchymal
Interventions
Quantitative ultrasound (DeepUSFF)
Device
Lead sponsor
Seoul National University Hospital
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boardman, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Phase 1 Interventional

A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NCT05395481
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Interventions
LY3849891, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
13
States / cities
Chandler, Arizona • Orange, California • Rialto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 17, 2026, 6:24 PM EDT
Recruiting Phase 1 Interventional

A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

NCT07358546
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
Efimosfermin alfa
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Rialto, California • Tampa, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 17, 2026, 6:24 PM EDT